Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
Saved in:
Main Authors: | Yamaguchi Ken-ichi (Author), Kishimoto Mitsumasa (Author), Okada Masato (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2012-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012) -
Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011) -
2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
by: Yokota S, et al.
Published: (2008) -
Tocilizumab in the treatment of rheumatoid arthritis and beyond
by: Shetty A, et al.
Published: (2014) -
Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis
by: V.V. Berejniy, et al.
Published: (2015)